Targets, Targets … Targeting
miRNAs exert their effects primarily by base-pairing with their target mRNAs in a complex with RISC (RNA-induced silencing complex), the same ribonucleoprotein machine responsible for siRNA-mediate gene silencing. Thus, the function of individual miRNAs should be ultimately defined by the identity of its downstream mRNA targets and by the strength of these miRNA-target interactions. It has been predicted that miRNAs regulate up to 50% of all mRNAs in human genome and that, on average, each miRNA targets hundreds of mRNAs. 7 Although identification of miRNA targets is a key step in dissecting miRNA mechanisms, comprehensive identification and quantitative analysis of the miRNA targets in the biologically or physiologically relevant context has been a major challenge.
Bioinformatics prediction combined with experimental validation has been used as a routine approach for miRNA target determination. Numerous freely available bioinformatics tools and algorithms can be used to identify candidate miRNA targets. 7 These algorithms are usually based on several criterions including: (1) sequence complementarity between miRNA seed region (the nucleotides 2 to 7 of the miRNA) and the mRNA 3Ј untranslated region (3ЈUTR); (2) phylogenetic conservation of miRNA recognition sites; and (3) thermal stability of putative miRNA:mRNA duplex. Although these bioinformatics approaches identify candidate miRNA targets, the consistency among different bioinformatics platforms is limited and the false-positive rate is high. Thus, putative targets identified in silico need to be validated experimentally. A commonly used experimental approach to validate candidate miRNA targets is the in vitro 3ЈUTR reporter assay. In this type of experiment, the 3ЈUTR of a putative miRNA target gene is fused with a luciferase reporter gene to permit convenient and quantitative measurement of miRNA-mediated target repression. Further validation studies involve analyses of miRNA target protein levels with miRNA gain or loss of function. Unfortunately, such studies are often limited by their low throughput and their dependence on the availability of suitable antibodies. These validation studies are often performed in artificial in vitro systems, and the results may have limited biological/physiological relevance, because target regulation by miRNAs is often sensitive to the cellular context.
Recent development of high-throughput genomic analyses has revolutionized biomedical research. It is not surprising that these cutting-edge technologies start to transform miRNA investigation. Both gene-chip microarray and the next-generation RNA-sequencing technologies have been introduced for miRNA target identification. 8 Using comparative transcriptome approaches, the Bartel laboratory reported that the expression levels of more than 84% of mammalian mRNAs were repressed by miRNAs, suggesting that mRNA destabilization may be the predominant mechanism for miRNA-mediated gene repression. 9 Given that the ultimate outcome of miRNA-mediated gene repression is reflected by a decrease of protein output, a proteomic analysis is more desirable for miRNA target identification, especially for identifying those targets that are not regulated by miRNAs at the mRNA level. Several proteomics studies of miRNA target using SILAC (stable isotope labeling by amino acids in cell culture) have been reported recently. 10, 11 The comparative transcriptome/proteome analysis allows largescale, quantitative measurement of mRNA/protein levels in cells. However, because expression of each individual target is only moderately regulated by miRNA in most cases, the mRNA/ protein level is not a sensitive readout for miRNA target identification. Another caveat for the comparative genomic/ proteomic approach is that some genes, which are not the bona fide miRNA targets but exhibit altered expression levels attributable to indirect secondary effects of miRNA manipulation, can be false-positively picked up. Clearly, more comprehensive, sensitive, and reliable technologies are desirable to precisely identify miRNA targets.
Promise to Target
A more direct biochemical approach of isolating and profiling mRNAs sequestered by RISC from certain biological contexts has recently been developed as a novel tool for miRNA target identification. This method promises to be a significant advance because it "directly" identifies mRNAs that are physically associated with the RISC (and therefore miRNAs). Using microarray profiling to analyze mRNAs coimmunoprecipitated with Argonaute2 (Ago2) protein, a key component of RISC (RISC-IP), Karginov et al recently identified a comprehensive set of miR-124a targets in HEK293 cells. 12 This study established that the RISC-IP, in combination with microarray profiling, is a valuable approach for miRNA target identification. However, microarray analysis demands large amounts of RNA sample, and microarray hybridization may introduce experimental noise. To overcome limitations of microarrays, RISCassociated mRNAs have been profiled by deep-sequencing approaches. 13, 14 These studies promise to provide improved methodology for miRNA target identification.
In this issue of Circulation Research, Matkovich et al identified many targets of 2 functionally and structurally distinct cardiac-expressed miRNAs, miR-133a and miR-499, in vivo, using an optimized RISC-IP and deep RNA sequencing (RISCome RNA profiling) approach (Figure) . 15 Standard RNAsequencing protocols require relatively large amounts of input RNA. This represents a hurdle for applying RNA sequencing to RNA that co-IPs with RISC, and therefore Matkovich et al optimized RNA-sequencing approaches for relatively little input RNA. They showed that RNA sample amplification before RNA-sequencing library construction caused loss of 47% of cardiac-expressed mRNAs and poor correlation between amplified and unamplified samples, indicating mRNA amplification bias. Matkovich et al then used a strategy that eliminated RNA amplification before library preparation and showed that resulting library yielded more representative expression profiles with improved correlation between low-mRNA input and reference samples. Applying these methods to analyze cardiac RISCassociated mRNA (the cardiac RISCome), the authors showed that the cardiac RISCome consisted of Ϸ15% of cardiac transcriptome. These RISC-enriched mRNAs represent a subset of predicted cardiac miRNA targets.
Next, Matkovich et al 15 nontransgenic (control) hearts yielded a set of miR-133a targets in cardiomyocytes. Notably, exogenous overexpression of miR-133a driven by the cardiac-specific Myh6 promoter did not appear to alter postnatal cardiac development nor lead to overt cardiac dysfunction, arguing against nonspecific, secondary effects on RISCome. Using the same approach, Matkovich et al investigated putative targets of miR-499, a second, unrelated, cardiac-specific miRNA. Together, the authors reported 209 and 81 targets for miR-133a and miR-499, respectively, in the heart. Importantly, the profiles of these 2 programmed RISComes showed little overlapping, suggesting that these miRNAs target distinct transcripts and, at the same time, highlighting the specificity of the method.
The study by Matkovich et al 15 substantially advances the state of the art in miRNA target identification. First, it provides an unbiased means to identify miRNA targets. Second, the RISCome was "programmed" and profiled in cardiomyocytes of intact mouse hearts, and therefore the in vivo physiologically relevance of miRNA and it targets is likely preserved. Third, no Ago2 overexpression was involved in this study. Most earlier studies used overexpression of tagged Ago2 protein to facilitate RISC-IP, 12, 13 but Ago2 overexpression could change the dynamics of RISC and lead to RISCome bias. Matkovich et al performed the RISC-IP using antibodies against the endogenous Ago2 protein. Finally, the RISC-IP was performed under a mild condition without sample cross-linking to minimize nonspecific target pull-down. As a result of these advances, the RISCsequencing approach of Matkovich et al promises to make it a valuable addition to our armamentarium for studying miRNA function.
Targeting Future
Although the study by Matkovich et al 15 significantly bolsters methods for miRNA target identification, some caveats remain. The "RISCome programming" approach is built on overexpression of a specific miRNA. Like all overexpression strategies, miRNA overexpression may induce nonphysiological interactions, leading to potential false-positive identification of miRNA-mRNA interactions. Likewise, overexpression of one miRNA may alter the distribution of other miRNAs in RISC nonspecifically. Using a miRNA loss-of-function model for RISCome deprogramming and miRNA target identification may result in greater specificity and meaningful outcomes than the described overexpression strategy, although loss of function may be experimentally more cumbersome because of frequent genetic miRNA redundancy. An additional limitation of the RISCsequencing approach is that it may not effectively address miRNA actions through mRNA destabilization, which is known to account for a substantial fraction of miRNA-mediated gene expression change. 7 The critical roles that miRNAs play in heart development and function and the ease of pharmacological manipulation on these noncoding RNAs have led to considerable interest in miRNAs as therapeutic targets in heart diseases. Determining the full spectrum of miRNA-mRNA interactions will greatly help us to define their biological functions and provide important insight for development of clinical therapeutics. Toward this goal, the optimized RISC-IP-RNA-sequencing approach of Matkovich et al promises to be a powerful tool for deciphering miRNA targets.
